Russian multicenter experience of using talazoparib in the treatment of patients with BRCA-associated metastatic breast cancer

Introduction. The presence of a germinal BRCA mutation occurs in 3–4% of all breast cancer (BC) patients with various biological subtypes, but significantly with a high frequency in patients with a triple negative biological subtype (in 10–20% of cases). For the treatment of patients with HER2-negat...

ver descrição completa

Detalhes bibliográficos

Principais autores:	T. Yu. Semiglazova, E. V. Lubennikova, L. V. Bolotina, R. V. Orlova, F. V. Moiseenko, A. V. Avramenko, E. V. Artemeva, S. A. Borozdina, A. A. Vakhitova, N. M. Volkov, I. P. Ganshina, Sh. A. Dzhalilova, L. G. Zhukova, B. S. Kasparov, A. A. Kachmazov, V. V. Klimenko, A. i. Kornietskaya, A. A. Meshcheryakov, A. A. Paichadze, A. N. Poltoratsky, O. E. Ryabishina, M. L. Stepanova, E. N Imyanitov
Formato:	Artigo
Idioma:	Russo
Publicado em:	Remedium Group LLC 2020-12-01
coleção:	Медицинский совет
Assuntos:	metastatic breast cancer brca mutation parp inhibitors talazoparib objective response disease control progression-free survival anemia thrombocytopenia
Acesso em linha:	https://www.med-sovet.pro/jour/article/view/5937
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!